BioCentury | May 1, 2020
Distillery Therapeutics

Thioredoxin reducing enzyme inhibitors for solid tumors

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer; head and neck cancer; lung cancer A Karolinska Institute team has identified compounds that inhibit TXNRD1, a thioredoxin reductase, that could treat colorectal, hypopharyngeal and lung cancers. TXNRD1 regenerates...
BioCentury | Jan 12, 2019

Warning: cash needed

A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech companies...
BioCentury | Jan 11, 2019
Company News

Trigr gets rights to ABL's bispecific antibody

ABL Bio Inc. (KOSDAQ:298380) granted Trigr Therapeutics Inc. (Irvine, Calif.) exclusive rights to TR009 (formerly ABL001, NOV1501), a bispecific antibody targeting δ like canonical Notch ligand 4 (DLL4) and VEGF. Trigr gets worldwide development and...
BioCentury | May 8, 2017
Distillery Therapeutics


INDICATION: Wounds Patient sample and mouse studies suggest a topical hydrogel that scavenges MCP-1 , CCL3 , CCL4 and other inflammatory factors could help treat chronic wounds. The hydrogel consisted of star-shaped PEG (starPEG) and glycosaminoglycans containing...
BioCentury | Mar 31, 2017
Politics, Policy & Law

Balancing act

Scott Gottlieb’s toughest political challenge before and after confirmation as FDA commissioner will not be from a hostile Congress, but rather from White House officials who believe the agency is an impediment to medical progress...
BioCentury | Feb 1, 2017
Clinical News

TTI-621: Ph I started

Trillium began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate single and multiple doses of 3 dose levels of intratumoral TTI-621 in about 54 patients. Trillium Therapeutics Inc. (TSX:TR; NASDAQ:TRIL), Toronto, Ontario Product:...
BioCentury | Dec 15, 2016
Clinical News

TTI-621: Preliminary Ph Ia data

Preliminary data from 18 patients with relapsed or refractory lymphomas in the dose-escalation Phase Ia portion of an open-label, North American Phase Ia/Ib trial showed that once-weekly IV TTI-621 led to 1 partial response. Trillium...
BioCentury | Aug 25, 2016
Targets & Mechanisms

Forty Seven and counting

With companies lining up to block CD47 for cancer, the cell surface protein is emerging as one of the top new targets in oncology. But the list of suitors could be about to get a...
BioCentury | Aug 22, 2016

Tioma's broad basket

Tioma Therapeutics Inc. will avoid putting its eggs in one basket and use last week's tranched $86 million series A round to launch a broad clinical program targeting CD47 . President and CEO John Donovan said...
BioCentury | Jul 25, 2016
Emerging Company Profile

Targeted phagocytosis

Alexo Therapeutics Inc. is developing variants of signal regulatory protein alpha that antagonize CD47 to increase macrophage phagocytosis induced by anticancer antibodies. Using the variants alongside antibody therapeutics could avoid on-target phagocytosis of healthy cells...
Items per page:
1 - 10 of 141